{
  "id": "chemotherapy_encounter_criteria",
  "type": "diagnostic_criteria",
  "name": "Chemotherapy Encounter - Management and Complications",
  "content": "ENCOUNTER FOR ANTINEOPLASTIC CHEMOTHERAPY:\n\nDEFINITION:\n- Healthcare encounter for administration of systemic chemotherapy\n- ICD-10: Z51.11 (encounter for antineoplastic chemotherapy)\n- May be inpatient or outpatient\n\nPRE-CHEMOTHERAPY ASSESSMENT:\n\n1. LABORATORY:\n   - CBC with differential (assess for cytopenias)\n   - CMP (renal/hepatic function, electrolytes)\n   - LFTs (many agents hepatically metabolized)\n   - Pregnancy test (if applicable)\n   - Additional: Tumor markers, specific organ function tests\n\n2. DOSE ADJUSTMENT CRITERIA:\n   - Renal function (GFR/CrCl) - many agents renally cleared\n   - Hepatic function (bilirubin, transaminases)\n   - Performance status (ECOG 0-4, Karnofsky 0-100)\n   - Prior toxicities\n\n3. SUPPORTIVE CARE:\n   - Antiemetics: 5-HT3 antagonists, NK1 antagonists, dexamethasone\n   - Hydration (nephrotoxic agents: cisplatin, ifosfamide)\n   - Growth factors: G-CSF if high risk neutropenia\n   - Tumor lysis prophylaxis: Allopurinol, rasburicase (high tumor burden)\n\nCOMMON CHEMOTHERAPY TOXICITIES:\n\n1. HEMATOLOGIC:\n   - Myelosuppression (nadir typically 7-14 days)\n   - Neutropenia: Infection risk, fever >38.3°C = emergency\n   - Anemia: Fatigue, may need transfusion or ESA\n   - Thrombocytopenia: Bleeding risk\n   \n   Management:\n   - G-CSF (filgrastim, pegfilgrastim) if ANC <1000 or febrile neutropenia\n   - Dose delay or reduction if severe\n\n2. GASTROINTESTINAL:\n   - Nausea/vomiting (acute <24h, delayed 24h-5days, anticipatory)\n   - Mucositis/stomatitis\n   - Diarrhea or constipation\n   - Hepatotoxicity\n   \n   Emetogenic potential:\n   - High (>90%): Cisplatin, AC regimen\n   - Moderate (30-90%): Carboplatin, oxaliplatin, doxorubicin\n   - Low (<30%): Taxanes, gemcitabine\n\n3. RENAL:\n   - Acute kidney injury (cisplatin, ifosfamide, methotrexate)\n   - Hemorrhagic cystitis (cyclophosphamide, ifosfamide)\n   - Electrolyte wasting (cisplatin: Mg, K)\n   \n   Prevention:\n   - Aggressive hydration\n   - Mesna (for cyclophosphamide/ifosfamide)\n   - Electrolyte replacement\n\n4. CARDIAC:\n   - Cardiomyopathy (anthracyclines: doxorubicin, lifetime dose limit)\n   - Arrhythmias\n   - Ischemia (5-FU, capecitabine)\n   \n   Monitoring:\n   - Baseline and periodic echocardiogram/MUGA for anthracyclines\n   - Consider dexrazoxane (cardioprotective)\n\n5. PULMONARY:\n   - Pneumonitis/fibrosis (bleomycin, methotrexate)\n   - Monitor O2 sat, PFTs\n\n6. NEUROLOGIC:\n   - Peripheral neuropathy (taxanes, platinum agents, vinca alkaloids)\n   - Encephalopathy (ifosfamide, high-dose methotrexate)\n   - Ototoxicity (cisplatin)\n\n7. DERMATOLOGIC:\n   - Alopecia (most agents, reversible)\n   - Hand-foot syndrome (capecitabine, doxorubicin)\n   - Extravasation injury (vesicants)\n\n8. HYPERSENSITIVITY:\n   - Infusion reactions (taxanes, platinum agents)\n   - Premedicate: Dexamethasone, antihistamines\n\nONCOLOGIC EMERGENCIES:\n\n1. FEBRILE NEUTROPENIA:\n   - Fever ≥38.3°C (101°F) OR ≥38°C (100.4°F) for 1h + ANC <500 (or <1000 with anticipated decline)\n   - EMERGENCY - Immediate broad-spectrum antibiotics within 1 hour\n   - Empiric: Cefepime, pip-tazo, or carbapenem\n   - Add vancomycin if: Hemodynamic instability, skin/soft tissue infection, positive blood culture for gram-positive\n   - Antifungal if persistent fever >4-7 days\n\n2. TUMOR LYSIS SYNDROME:\n   - Massive tumor cell death → release of intracellular contents\n   - Hyperkalemia, hyperphosphatemia, hypocalcemia, hyperuricemia\n   - AKI from uric acid precipitation\n   - Prevention: Allopurinol, rasburicase, aggressive hydration\n   - Treatment: Electrolyte management, dialysis if refractory\n\n3. SUPERIOR VENA CAVA SYNDROME:\n   - Obstruction of SVC → facial/upper body swelling, dyspnea\n   - Urgent radiation or chemotherapy\n\n4. SPINAL CORD COMPRESSION:\n   - Back pain, weakness, sensory changes, bowel/bladder dysfunction\n   - MRI urgent, dexamethasone, radiation/surgery\n\n5. HYPERCALCEMIA OF MALIGNANCY:\n   - Ca >12 mg/dL: Nausea, confusion, polyuria\n   - Treatment: IV fluids, bisphosphonates, calcitonin\n\nQUALITY OF LIFE:\n- Assess ECOG performance status\n- Screen for distress, depression, anxiety\n- Nutritional support\n- Palliative care integration for symptom management\n- Advance care planning\n\nFOLLOW-UP:\n- Assess for delayed toxicities\n- Monitor for recurrence (imaging, tumor markers)\n- Survivorship care plan\n- Screen for late effects (secondary malignancies, organ dysfunction)\n\nDOSE MODIFICATIONS:\n- Hold if: ANC <1000, platelets <50K (varies by regimen), grade 3-4 non-hematologic toxicity\n- Reduce 20-25% for grade 3-4 toxicity\n- Discontinue if life-threatening toxicity",
  "metadata": {
    "category": "oncology",
    "diagnosis": "chemotherapy_encounter",
    "priority": "HIGH",
    "source": "NCCN Guidelines, ASCO Clinical Practice"
  }
}
